PMC:7253235 / 32350-32567 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1095","span":{"begin":104,"end":108},"obj":"Gene"},{"id":"1101","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"1102","span":{"begin":143,"end":151},"obj":"Chemical"}],"attributes":[{"id":"A1095","pred":"tao:has_database_id","subj":"1095","obj":"Gene:6622"},{"id":"A1101","pred":"tao:has_database_id","subj":"1101","obj":"MESH:C502936"},{"id":"A1102","pred":"tao:has_database_id","subj":"1102","obj":"MESH:D013256"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T249","span":{"begin":173,"end":174},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T250","span":{"begin":197,"end":207},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T86","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T87","span":{"begin":104,"end":106},"obj":"Chemical"},{"id":"T88","span":{"begin":109,"end":119},"obj":"Chemical"},{"id":"T89","span":{"begin":143,"end":151},"obj":"Chemical"}],"attributes":[{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"}],"text":"Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T206","span":{"begin":0,"end":217},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]."}

{"project":"2_test","denotations":[{"id":"32462289-32212881-24380981","span":{"begin":209,"end":211},"obj":"32212881"},{"id":"32462289-29207939-24380982","span":{"begin":213,"end":215},"obj":"29207939"}],"text":"Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]."}